source
- BMS's Cobenfy faces market hurdles as side effects limit uptake, MapLight eyes opportunityThe FDA approved Bristol Myers Squibb's Cobenfy in 2024, marking the first novel schizophrenia treatment in 35 years and raising hopes for a new therapeutic approach. Since its launch, the drug ha…
- RevMed partners with BeOne for Asian rights to RAS drugs as MoonLake reports Phase 3 successRevMed and BeOne have entered a partnership granting BeOne rights to commercialize RevMed’s RAS pathway drugs in selected Asian markets. The agreement also includes collaboration on upcoming clini…